



## REGENXBIO to Participate in Upcoming Investor Conferences

May 4, 2022 11:05 AM EDT

ROCKVILLE, Md., May 4, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:

**Bank of America Securities 2022 Healthcare Conference**

**Date:** Tuesday, May 10, 2022

**Location:** Encore Hotel, Las Vegas, NV

**Presentation:** Tuesday, May 10, 2022 at 4:00 p.m. PT

**UBS Global Healthcare Conference 2022**

**Date:** Tuesday, May 24, 2022

**Location:** Lotte New York Palace, New York, NY

**Presentation:** Tuesday, May 24, 2022 at 10:45 a.m. ET

A webcast of both presentations can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

**About REGENXBIO Inc.**

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

**Contacts:**

Dana Cormack  
Corporate Communications  
[dcormack@regenxbio.com](mailto:dcormack@regenxbio.com)

Investors:  
Chris Brinzey, ICR Westwicke  
339-970-2843  
[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301539404.html>

SOURCE REGENXBIO Inc.